Prudential Financial
GLUE icon

Prudential Financial’s Monte Rosa Therapeutics GLUE Stock Holding History

Prudential Financial’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$290K Sell
11,975
-44,305
-79% -$837K ﹤0.01% 2112
2026
Q1 		$926K Buy
+56,280
New +$1.08M ﹤0.01% 1629
2025
Q4 		– Sell
-12,054
Closed -$89.3K – 2303
2025
Q3 		$89.3K Hold
12,054
– – ﹤0.01% 2288
2025
Q2 		$54.4K Buy
+12,054
New +$53.8K ﹤0.01% 2339
2022
Q1 		– Sell
-73,845
Closed -$1.51M – 2637
2021
Q4 		$1.51M Buy
+73,845
New +$1.55M ﹤0.01% 1678

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Prudential Financial's GLUE Position: Q2 2026 in Review

Prudential Financial reduced its Monte Rosa Therapeutics (GLUE) stake by 79% in Q2 2026, selling an estimated $837K and leaving 11,975 shares worth $290K. The position accounts for ﹤0.01% of the portfolio, ranked #2112.

Prudential Financial first reported a position in GLUE in Q4 2021 and has held it in 5 quarters since. The position peaked at $1.51M in Q4 2021. 193 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Prudential Financial held 11,975 shares of Monte Rosa Therapeutics worth $290K as of Q2 2026.
  • Prudential Financial sold 44,305 Monte Rosa Therapeutics shares in Q2 2026, an estimated $837K.
  • Monte Rosa Therapeutics made up ﹤0.01% of Prudential Financial's portfolio in Q2 2026, its #2112 holding.
  • Prudential Financial first reported a position in Monte Rosa Therapeutics in Q4 2021 and has held it in 5 quarters since.
  • Prudential Financial's Monte Rosa Therapeutics position peaked at $1.51M in Q4 2021.
  • 193 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Prudential Financial's 13F filing for Q2 2026, filed 12 Aug 2026.